Oncological Adjuvant Trials in Melanoma

Mar 17, 2021 4 min read
Oncological Adjuvant Trials in Melanoma

Major adjuvant oncological trials in melanoma show a significant survival benefit in patients with completely resected stage III disease, as discussed here.

5 Key Points

These major adjuvant oncological trials in melanoma, which were based on the previous AJCC 7th Edition for Staging Melanoma, showed a significant survival benefit in patients with completely resected stage III disease. This can be summarised in 5-Key Points.
  1. EORT 18,201 showed a significant survival benefit with adjuvant ipilimumab.
  2. CheckMate 238 showed a significant survival benefit of adjuvant nivolumab over ipilimumab.
  3. Combi-AD showed a significant survival benefit of adjuvant dabrafenib + trametinib in BRAF+ disease.
  4. EORTC 1325/KeyNote 054 showed a significant survival benefit of adjuvant Pembrolizumab.
  5. BRIM-8 showed a modest survival benefit of adjuvant vemurafenib in Stage 2C-3C disease.

EORTC 18,701

Eggermont et al​1​ phase 3 trial in 2016 showed significant survival benefit at 5-years for adjuvant ipilimumab (checkpoint inhibitor) in Stage 3A-3C disease.

Background

  • A phase 3 study following up from the data of a phase 2 trial( ipilimumab at doses of 0.3 mg, 3 mg, and 10 mg per kilogram)
  • This phase 3 trial evaluated ipilimumab at a dose of 10 mg per kilogram in patients who had undergone complete resection of stage III melanoma.

Methods

  • Patients had undergone complete resection of stage III cutaneous melanoma
  • Random assignment to ipilimumab (475 patients) or placebo (476) medication.
  • For up to 3 years or until disease recurrence or an unacceptable level of toxic effects occurred.
  • Primary Endpoint: Recurrence-free survival.
  • Secondary Endpoints: overall survival, distant metastasis–free survival, and safety.

Results

  • Median follow-up of 5.3 years,
  • Recurrence-free survival: Ipilimumab was 40.8%, placebo was 30.3%.
  • Overall survival: Ipilimumab was 65.4%, placebo was 54.4%.
  • Rate of distant metastasis: Ipilimumab was 48.3%, placebo was 38.9%.
  • 1.1% treatment related death in the Ipilimumab group.

Conclusion

Ipilimumab adjuvant therapy results in significantly higher rates of

  • Recurrence-free survival
  • Overall survival
  • Distant metastasis–free survival.

There were more immune-related adverse events with ipilimumab than with placebo.


CheckMate 238

Webster et al​2​ in 2018 showed a significant relapse-free survival benefit of nivolumab over ipilimumab in resected Stage 3b-4 disease.

Methods

  • Patients were ≥15 yrs with complete resection of stage IIIB/C or IV melanoma,
  • 906 patients were randomised to treat nivolumab over ipilimumab.
  • Primary endpoint was relapse free survival.

Results

  • 24-month follow-up
  • Relapse-Free Survival: NIVO 171/453, IPI 221/453
  • Distant Metastasis-Free Survival: NIVO 70.5% and IPI 63.7%

Conclusion

  • NIVO demonstrated a sustained efficacy benefit vs IPI in pts with resected stage III/IV melanoma at high risk of recurrence, regardless of disease stage, PD-L1 expression, or BRAF mutation status.
  • Adjuvant Nivolumab is approved by the EMA and by NICE for patients with resected 3A-4 disease.

Combi-AD

The Combi-AD study​3​ showed a 47% reduction in risk of developing metastasis, or death in the group treated with dabrafenib + trametinib. This was adjuvant treatment for BRAF positive resected 3A-3C disease.

Background

  • Combination therapy with BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib improved survival in advanced BRAF+ melanoma.
  • Aim is to determine if adjuvant dabrafenib+trametinib improve outcomes in resected, stage III BRAF+ melanoma

Methods

  • Double-blind, placebo-controlled, phase 3 trial,
  • Patients had completely resected, stage III melanoma with BRAF V600E or V600K mutations.
  • Primary endpoint: relapse-free survival
  • Secondary endpoints: overall survival, distant metastasis–free survival, freedom from relapse, and safety.

Results

  • Median follow-up of 2.8 years with 840 randomised patients.
  • 3-year relapse-free survival: 59% in combination therapy, 39% placebo
  • 3-year overall survival: 86% in combination therapy, 77% placebo.
  • Safety profile of dabrafenib plus trametinib was consistent with normal standards.

Conclusion

  • Adjuvant use of dabrafenib + trametinib significantly lowers risk of recurrence in patients with stage III melanoma with BRAF V600E or V600K mutations.
  • It was not associated with new toxic effects

EORTC 1325/KeyNote 054

This study​4​ showed the role of Pembrolizumab (a PD-1 inhibitor) to increase relapse free survival in high-risk completely resected stage III melanoma patients.

Background

  • Pembrolizumab (programmed death 1 (PD-1) inhibitor) prolongs progression-free and overall survival among patients with advanced melanoma.
  • Aim to evaluate pembrolizumab as adjuvant therapy in patients with resected, high-risk stage III melanoma in a phase 3 double-blind trial.

Methods

  • Patients with completely resected stage III melanoma were randomly assigned to pembrolizumab (514 patients) or placebo (505 patients)
  • Primary endpoints: Recurrence-free survival

Results

  • Median follow-up of 15 months,
  • Recurrence-free survival: Pembrolizumab 75.4%, placebo 61%.
  • 14.7% of the patients in the pembrolizumab group had adverse effects, with one treatment-related death due to myositis in the pembrolizumab group.

Conclusion

  • As adjuvant therapy for high-risk stage III melanoma, pembrolizumab significantly increases recurrence-free survival than placebo, with no new toxic effects identified.

Brim-8 Study

The BRIM8 study​5​ examined the role of the adjuvant vemurafenib in Stage 2C-3C disease. This showed a modest impact on RFS and is not being taken forward.

Background

  • Hypothesis: Systemic adjuvant treatment might mitigate the high risk of disease recurrence in patients with resected stage IIC–III melanoma.
  • Aim: Evaluate adjuvant vemurafenib monotherapy in patients with resected, BRAF V600 mutation-positive melanoma.

Methods

  • Phase 3, international, double-blind, randomised, placebo-controlled study
  • 498 adults with histologically confirmed stage IIC–IIIA–IIIB (cohort 1) or stage IIIC (cohort 2) BRAF V600 mutation-positive melanoma that was fully resected.
  • Patients were randomly assigned to receive twice-daily adjuvant oral vemurafenib 960 mg tablets or matching placebo for 52 weeks (13 × 28-day cycles).
  • Primary endpoint was disease-free survival in the intention-to-treat population, evaluated separately in each cohort.

Outcome

  • The primary endpoint of disease-free survival was not met in cohort 2, and therefore the analysis of cohort 1 showing a numerical benefit in disease-free survival must be considered exploratory only.
  • 1 year of adjuvant vemurafenib was well tolerated, but might not be an optimal treatment regimen in this patient population.

References

  1. 1. Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med. November 2016:1845-1855. doi:10.1056/nejmoa1611299
  2. 2. Weber JS, Mandalà M, Del Vecchio M, et al. Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238). JCO. May 2018:9502-9502. doi:10.1200/jco.2018.36.15_suppl.9502
  3. 3. Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated Melanoma. N Engl J Med. November 2017:1813-1823. doi:10.1056/nejmoa1708539
  4. 4. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. May 2018:1789-1801. doi:10.1056/nejmoa1802357
  5. 5. Maio M, Lewis K, Demidov L, et al. Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. The Lancet Oncology. April 2018:510-520. doi:10.1016/s1470-2045(18)30106-2
In this Article
Great! Next, complete checkout for full access to thePlasticsFella.
Welcome back! You've successfully signed in.
You've successfully subscribed to thePlasticsFella.
Success! Your account is fully activated, you now have access to all content.
Success! Your billing info has been updated.
Your billing was not updated.